OncLive is reporting the preliminary research in the clinical trial for Trop2-ADC is looking promising. While not RET specific, for those that advance or do not respond to RET specific therapies, and don't have another targetable mutation, this can be another alternative treatment. This article highlights some initial pros and cons and highlights future potential. From the article,
If the efficacy, including the DOR data hold up, and particularly if the pulmonary toxicity can be controlled at the dose that more than half the patients on TROPION-PanTumor01 (NCT03401385) received, datopotamab deruxtecan does have the potential to change our second-line treatment approach,” said Garon, professor of medicine, David Geffen School of Medicine, and director of Thoracic Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles.
Read more here.